LONDON, Jan 8 (Reuters) - Iceland’s Actavis, one of the world’s top makers of generic drugs, is to be offered for sale by its private-equity owners in an auction that could raise $6 billion or more, three people familiar with the situation said.
Merrill Lynch, which was hired by the Icelandic group last year to review its strategic options, is to kick off the formal auction process shortly and a deal could be clinched within three to five months, the sources told Reuters on Thursday.
“We are now much closer to a sale process ... quite possibly in the coming weeks,” said one source, noting that Actavis had just solved a problem at a U.S. factory that removed a key hurdle to a sale.
Actavis spokeswoman Hjordis Arnadottir declined to comment on the auction but said the company had been reviewing its options -- including merging with another firm, acquiring a rival or selling the business -- for several months.
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.